Thomas Clozel

Chief Executive Officer and Co-founder, OWKIN
New York, New York,United States
Find Thomas Clozel's Email
Find Thomas Clozel's Phone

Who Is Thomas Clozel?

Total Experience18 years
CompanyOWKIN
CountryUnited States

Thomas Clozel is the co-founder and CEO of Owkin, a French-American AI biotechnology company that uses artificial intelligence and federated learning to discover and develop better treatments for patients. With a background as a clinical research doctor and former assistant professor in clinical hematology, Dr. Clozel transitioned into entrepreneurship to leverage AI's potential in revolutionizing medical research and drug development. He holds an MD from Paris Descartes University and a PhD in Health Economics. His vision is to build a global research network through Owkin, connecting leading academic institutions and pharmaceutical companies to accelerate therapeutic innovation while prioritizing patient data privacy and security.

How Did Thomas Clozel's Career Path Shape Their Journey?

Thomas Clozel's work history includes a series of influential roles in various companies. Here is a detailed list of his professional journey:

OWKIN - Chief Executive Officer and Co-founder(2016 to Present)
Bioptimus - Non operational cofounder(2024 to Present)
XPRIZE - Brain trust(2024 to Present)
Université Paris-Saclay - Member Board of Directors(2024 to Present)
Cure51 - Non operational cofounder(2024 to Present)
EQT Group - Advisor(2025 to Present)
Sofinnova Partners - Venture advisor(2022 to Present)
GRACE - Advisor(2023 to Present)
Fragment (YC S23) - Seed Investor(2023 to 2023)
Osium AI (YC S23) - Seed Investor(2023 to 2023)

What Are Thomas Clozel's Key Achievements?

Co-founder and CEO of Owkin

Successfully co-founded Owkin in 2016, building it into a leading AI biotechnology company focused on discovering and developing new drugs and diagnostic tools to improve patient outcomes using AI and federated learning.

Pioneering Federated Learning in Healthcare

Championed the application of federated learning in medical research, enabling collaborative AI model training on distributed datasets without moving sensitive patient data, thereby enhancing privacy and security.

Securing Major Funding and Strategic Partnerships

Led Owkin through significant funding rounds, including a notable investment from Sanofi, and established strategic collaborations with major pharmaceutical companies (like BMS, Amgen) and research institutions worldwide.

Advancing AI for Drug Discovery and Development

Driving Owkin's mission to use AI to identify new drug targets, predict treatment efficacy, and optimize clinical trial design, contributing to the acceleration of bringing new therapies to patients.

Recognition as an Innovator

Recognized for his contributions to AI in healthcare and entrepreneurship, including features in prominent industry publications and leadership forums discussing the future of medicine.

What's Thomas Clozel's Educational Background?

research fellowship, Hematology-oncology

Weill Medical College of Cornell University - Year 2009

Clinical rotation, Neurology Department

Mount Sinai School of Medicine of New York University - Year 2006

Buying Intent Signals for Thomas Clozel

Highperformr Signals uncover buying intent and give you clear insights to target the right people at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance

Company Overview

OWKIN
Total employees380
HeadquartersParis
Founded2016

OWKIN is an AI biotechnology company that specializes in using artificial intelligence and machine learning, particularly federated learning, for medical research and drug discovery. They aim to connect the global healthcare ecosystem, enabling researchers to securely analyze vast amounts of patient data from different institutions without data centralization, thus preserving patient privacy. OWKIN's platforms and services help to identify new drug targets, develop diagnostic tools, predict treatment outcomes, and accelerate clinical trials, ultimately aiming to improve patient care and bring precision medicine to reality.

OWKIN Funding Information
Unknown - Total Funding Raised
$25M - Most recent funding amount
5 - Number of funding rounds
7 Jul, 2022 - Latest funding round
Lead Investors:
Sanofi
Bristol Myers Squibb
GV (Google Ventures)
Mubadala Capital
Bpifrance (via its Large Venture fund)
Cathay Innovation
MACSF
F-Prime Capital
General Catalyst

Highperformr's free tools for company research

Find contact info

Get verified emails, phone numbers, and LinkedIn profile details

Find similar contacts

Discover contacts with similar roles, seniority, or companies

Perform deep contact research

Uncover insights like skills, work history, social links, and more

Discover, research and enrich contacts with Highperformr — Smarter, Faster

Explore contacts in-depth — from verified emails and phone numbers to LinkedIn activity, job changes, and more — all in one powerful view.

Highperformr AI helps you surface the right people and enrich your CRM with live, accurate contact insights so your teams can connect faster and close smarter.

  • Track signals like job change, promotion, and LinkedIn activity
  • Enrich contacts with verified email, phone, and social data instantly
  • Automate enrichment and updates with powerful workflows
  • Sync enriched contact info directly into your CRM and tools

Thousands of contacts — including decision-makers, influencers, and ICP matches — are just a search away.

Thousands of companies, including, are just a search away.